Acumen Pharmaceuticals Inc.
ABOS | NASDAQ
$2.59
-$0.06 (-2.26%)
At close: Sep 21, 2026, 4:00 PM ET
$2.60
+$0.01 (+0.53%)
Pre-market:
Sep 22, 2026, 5:37 AM ET
Company Profile
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Key Executives
| Name | Position |
|---|---|
| Daniel J. O'Connell | Chief Executive Officer & Director |
| Derek Meisner | Chief Legal Officer & Corporate Secretary |
| Matt Zuga | Chief Financial Officer & Chief Business Officer |
| Russell Barton | Chief Operating Officer |
| Alex Braun | Vice President & Head of Investor Relations |
| Caleb E. Finch | Co-Founder |
| Grant A. Krafft | Co-Founder |
| James Doherty | President & Chief Development Officer |
| Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller |
| William L. Klein | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2026 | S-8 | Filing |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 12, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 4 | Filing |
| Jun 16, 2026 | 8-K | Current Report |
| Jun 10, 2026 | 4 | Filing |
| Jun 05, 2026 | 4 | Filing |
| Jun 05, 2026 | 4 | Filing |
| Jun 05, 2026 | 4 | Filing |
| Jun 05, 2026 | 4 | Filing |
Acumen Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jun 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Daniel J. O'Connell |
Contact Details
1210-1220 Washington St. Newton,
Massachusetts 02465 United States
Stock Details
| Ticker Symbol | ABOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001576885 |
| CUSIP Number | 00509G209 |
| ISIN Number | US00509G2093 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove ABOS